More HMDP Coming in Late March, Radiopharmaceutical Manufacturer Says

Following supply issues starting in January, ASNC is maintaining close contact with manufacturers of Tc-99m pyrophosphate (PYP) and Tc-99m hydroxymethylene diphosphonate (HMDP or HDP). Curium, a manufacturer of PYP and HMDP, reports that its next HMDP release will be in late March. A company spokesperson also confirmed that a PYP lot was released in mid-February.

ASNC encourages members to contact their local radiopharmacies for the latest information on supplies of HMDP and PYP in their areas.

Helpful Resources

For guidance on using HMDP and PYP, register to attend this week’s virtual Masterclass in Cardiac Amyloidosis, March 13-15. Complimentary for all attendees, Masterclass will sharpen your skills for suspecting, diagnosing, treating, and managing transthyretin amyloidosis. Experts will update you on the rapidly changing landscape of cardiac amyloidosis, including disease pathogenesis, mechanisms for facilitating early diagnosis, diagnostic techniques and pitfalls, available and emerging radiotracers, treatment options, management strategies, monitoring therapeutic response, starting an amyloid center, and much more! Register now!

ASNC’s Think Amyloid poster is available here.

You may also download these helpful resources:

• ASNC Information Statement: Radiopharmaceutical Supply Disruptions and the Use of 99mTc-Hydroxymethylene Diphosphonate as an Alternative to 99mTc-Pyrophosphate for the Diagnosis of Transthyretin Cardiac Amyloidosis
• Think Amyloid Poster: Optimizing Imaging with Tc-99m HDP and Tc-99m PYP for Transthyretin Cardiac Amyloidosis

Relevant Research

A study published in the new issue of the Journal of Nuclear Cardiology tackles whether either PYP or HMDP outperforms the other in cardiac amyloid radionuclide imaging. Gregorio Tersalvi, MD, and colleagues compared scan results, ATTR-CM prevalence, and myocardial-to-blood-pool discrimination for 992 consecutive patients who underwent SPECT/CT for suspected ATTR-CM at a single referral center. In an accompanying editorial, Shivda Pandey, MBBS, FASNC, and Frederick L. Ruberg, MD, wrote that, overall, the study’s findings are reassuring.

View JNC